Tricor 145 mg

Matlapa a koahetsoeng ka filimi ea 145 mg

Letlapa le leng le na le

ntho e sebetsang - fenofibrate ea micronized 145 mg,

Baeti: hypromellose, sodium docusate, scrose, sodium lauryl sulfate, lactose monohydrate, microcrystalline silonized cellulose, crospovidone, magnesium stearate.

Ho hlophisoa ha khetla: Opadry OY-B-28920 (joala ba polyvinyl, titanium dioxide E171, talc, soya bean lecithin, xanthan gum).

Matlapa a nang le sebopeho sa oval a koahetsoeng ka koae e tšoeu ea filimi, e ngotsoe ka "145" ka lehlakoreng le leng le logo ea k'hamphani ka lehlakoreng le leng.

Melemo ea pharmacological ea lithethefatsi Tricor 145 mg

fenofibrate ke derivative ea fibroic acid. Phello ea eona profil ea lipid, e ileng ea bonoa bathong, e kenelloa ke ts'ebetso ea receptor e entsoeng ke proliferating factor alpha mofuta peroxisome (PPARA).
Ka ts'ebetso ea PPARα, fenofibrate e eketsa matla a lipolysis le ho felisoa ha likaroloana tse nang le TG tse tsoang plasma ea mali ka ho kenya lipoprotein lipase le ho fokotsa sebopeho sa apoprotein CIII. Ts'ebetso ea PPARcy e boetse e baka keketseho ea mofuta oa li-apoproteins AI le II.
Litlamorao tse kaholimo tsa fenofibrate ho LP li lebisa ho fokotseha hoa likarolo tsa VLDL le LDL, tse nang le apoprotein B, le keketseho ea karoloana ea HDL, e nang le apoproteins AI le II.
Ntle le moo, ka ho fetola motsoako le catabolism ea sekhechana sa VLDL, fenofibrate e eketsa ho hlaka ha LDL le ho fokotsa palo ea LDL, boemo ba eona bo eketsoang ka phenotype ea atherogenic lipoprotein, eo hangata e bonoang ho bakuli ba kotsing ea lefu la coronary artery.
Nakong ea liteko tsa bongaka tsa fenofibrate, boemo ba cholesterol e felletseng bo fokotsehile ka 20-25%, TG ka 40-55%, mme boemo ba cholesterol ea HDL bo eketsehile ka 10-30%. Ho bakuli ba nang le hypercholesterolemia, moo boemo ba cholesterol ea LDL e fokotsoang ke 20- 35%, phello e felletseng e amanang le k'holeseterole e ne e amana le ho fokotseha ha tekanyo ea cholesterol e felletseng ho cholesterol ea HDL, LDL cholesterol ho HDL cholesterol kapa apoprotein AI, e leng matšoao a atherogenic.
Ka lebaka la eona phello ea cholesterol ea LDL le triglycerides, kalafo ea fenofibrate e na le phello e ntle ho bakuli ba nang le ntle le hypercholesterolemia hammoho le hypertriglyceridemia, ho kenyeletsa hyperlipoproteinemia ea bobeli, e tšoanang le e fumanoeng mofuteng oa lefu la tsoekere la II.
Ho fihla joale, ha ho na liphetho tsa lithuto tsa nako e telele tse laoloang ho bonts'a katleho ea fenofibrate e amanang le thibelo ea mantlha le ea bobeli ea mathata a atherosclerosis.
Li-amana tse eketsehileng tsa cholesterol (xanthoma tendinosum et tuberosum) li ka fokotseha haholo kapa tsa nyamela ka ho felletseng nakong ea kalafo ea fenofibrate.
Ho bakuli ba nang le maemo a phahameng a fibrinogen ba ileng ba phekoloa ka fenofibrate, ho ile ha hlokomeleha ho fokotseha ho hoholo hoa paramente ena. Matšoao a mang a ho ruruha, joalo ka CRP, le ona a fokotsehile ka kalafo ea fenofibrate.
Phello ea uricosuric ea fenofibrate, e lebisang ho fokotseha hoa litekanyetso tsa uric acid ka 25%, e ka nkuoa e le phello e ntle ho bakuli ba dyslipidemia hammoho le hyperuricemia.
Ho fumanoe hore fenofibrate e ka fokotsa ho kopana ha liplatelese tse hlahisoang ke adenosine diphosphate, arachidonic acid, le epinephrine.
Litafole tsa Tricor tsa 145 mg li na le fenofibrate ka mokhoa oa nanoparticles.
Suction
Ho kenella ka bongata plasma ea mali ho fihlella lihora tse 2 ka mor'a ho buuoa ka molomo. Ts'oarello ea plasma ea mali e tsitsitse ka kalafo e sa feleng.
Ho fapana le litokisetso tse ling tsa fenofibrate, khatello e phahameng ka ho fetisisa setsing sa mali le ho amoheloa ha moriana ka kakaretso, o nang le fenofibrate nanoparticles, ha o anngoe ke tšebeliso ea lijo. Ka hona, matlapa a Traicor 145 mg a ka sebelisoa ho sa tsotelehe takatso ea lijo.
Phuputso e mabapi le ho amoheloa ha moriana, o neng o kenyelletsa ho tsamaisoa ha litafole tsa 145 mg ho banna le basali ba phetseng hantle ka mpeng e se nang letho le nakong ea lijo tse nang le mafura a mangata, ho bontšitse hore tšebeliso ea lijo ha e ame ho koaloa (AUC le mahlakore a mangata a plasma) a fenofibric acid.
Tsamaiso
Fenofibric acid e na le tekanyo e phahameng ea ho tlama ho plasma albin (ho feta 99%).
Metabolism le Excretion
Kamora ho tsamaisoa ka molomo, fenofibrate e potlakisa hydrolyzed ke litekanyetso ho metabolite e sebetsang ea fenofibric acid. Fenofibrate e sa fetoheng plasma ea mali ha e fumanoe. Fenofibrate ha se substrate ea CYP 3A4 ebile ha e nke karolo ho hepatic microsomal metabolism.
Fenofibrate e hlohloreloa haholo ka har'a moroto. E batla e tlositsoe ka botlalo ka matsatsi a 6. E sirellelitsoe haholo ka sebopeho sa fenofibric acid mme e kopana le glucuronide. Ho bakuli ba tsofetseng, tumello ea plasma eohle ea fenofibric acid ha e fetohe.
Lithuto tsa Kinetic kamora ho nka tekanyetso e le 'ngoe le kalafo e telele li bontšitse hore fenofibrate ha e kopeloe ke' mele.
Fenofibric acid ha e hlahisoe ke hemodialysis.
Bophelo ba halofo ea fenofibric acid e tsoang plasma ea mali ke lihora tse 20.

Melemo ea pharmacological

Mofumahali

Letlapa la Tricor le koahetsoeng ka 2005 mg le na le "mg" ea "fenofibrate" "micenised" fenofibrate ka mokhoa oa nanoparticles.

Suction. Kamora ho tsamaisoa ha Tricor ka molomo, 145 mg ea Cmax (mahloriso a phahameng) a fenofibroic acid e fihlella ka mor'a lihora tse 2 000. Ka tšebeliso ea nako e telele, khatello ea fenofibroic acid ka har'a plasma e lula e tsitsitse, ho sa tsotelehe likarolo tsa motho ka mong. Ho fapana le sebopeho se fetileng sa fenofibrate, Cmax ho plasma le phello e felletseng ea fenofibrate ea micronized ka sebopeho sa nanoparticles (Tricor 145 mg) ha ea itšetleha ka tšebeliso ea lijo ka nako e le 'ngoe (ka hona, moriana o ka nooa nako efe kapa efe, ho sa tsotelloe tšebeliso ea lijo).

Fenofibroic acid e thata ebile e feta 99% e tlameletsoe ho plasma albin.

Metabolism le excretion

Kamora ho tsamaisoa ka molomo, fenofibrate e potlakisa hydrolyzed ke litekanyetso tsa fenofibroic acid, e leng metabolite ea eona e ka sehloohong. Fenofibrate ha e bonoe ho plasma. Fenofibrate ha se karoloana ea CYP3A4, ha e amehe ho microsomal metabolism ho sebete.

Fenofibrate e pepesitsoe haholo ka har'a moroto ka mokhoa oa fenofibroic acid le glucuronide conjugate. Pele ho feta matsatsi a 6. fenofibrate e hloekisoa hoo e ka bang ka botlalo. Ho bakuli ba tsofetseng, ho hlakisoa ka botlalo ha fenofibroic acid ha ho fetohe. Bophelo ba halofo ea fenofibroic acid (T1 / 2) ke lihora tse ka bang 20. Ha hemodialysis e sa bonts'e. Boithuto ba Kinetic bo bontšitse hore fenofibrate ha e bokellane ka mor'a tekanyetso e le 'ngoe le ts'ebeliso ea nako e telele.

Mofumahali

Tricor ke moemeli ea fokotsang lipid ho tsoa sehlopheng sa lintho tse tsoang ho fibroic acid. Fenofibrate e na le bokhoni ba ho fetola litaba tsa lipid 'meleng ka lebaka la ts'ebetso ea li-receptor tsa PPAR-α (li-alpha receptors tse hlahisoang ke proliferator ea peroxisome).

Fenofibrate e ntlafatsa lipoprotein ea plasma le excretion ea lipoprotein ea atherogenic e nang le litaba tse phahameng tsa triglycerides ka ho kenya tšebetsong li-receptor tsa PPAR-α, lipoprotein lipase le ho fokotsa sebopeho sa apoprotein C-III (apo C-III). Litlamorao tse hlalositsoeng kaholimo li lebisa ho fokotseheng ha litaba tsa LDL le VLDL, tse kenyelletsang apoprotein B (apo B), le keketseho ea litaba tsa likaroloana tsa HDL, tse kenyeletsang apoprotein A-I (apo A-I) le apoprotein A-II (apo A-II). . Ntle le moo, ka lebaka la khalemelo ea tlolo ea synthetic le catabolism ea VLDL, fenofibrate e eketsa ho hlaka ha LDL mme e fokotsa litaba tsa likarolo tse nyane le tse teteaneng tsa LDL (keketseho ea LDL ena e bonoa ho bakuli ba nang le atherogenic lipid phenotype mme e amana le kotsi e kholo ea CHD).

Nakong ea lithuto tsa bongaka, ho ile ha hlokomeloa hore ts'ebeliso ea fenofibrate e fokotsa boemo ba cholesterol e felletseng ka 20-25% le triglycerides ka 40-55% ka keketseho ea boemo ba HDL-C ka 10-30%. Ho bakuli ba nang le hypercholesterolemia, moo boemo ba Chs-LDL bo fokotsoang ke 20-35%, ts'ebeliso ea fenofibrate e lebisitse ho fokotseha ha litekanyetso: kakaretso ea Chs / Chs-HDL, Chs-LDL / Chs-HDL le kae B /apo A-I, tse matšoao a atherogenic kotsi.

Ho na le bopaki ba hore li-fibrate li ka fokotsa khafetsa ea liketsahalo tse amanang le lefu la pelo, empa ha ho na bopaki ba ho fokotseha ha lefu le bolaeang kahare ho thibelo ea mantlha kapa ea bobeli ho lefu la pelo le pelo.

Nakong ea kalafo ka fenofibrate, li-depositi tsa "extra" tsa "XC" (tendon le tuberous xanthomas) li ka fokotseha haholo le ho nyamela ka botlalo. Ho bakuli ba nang le maemo a phahameng a fibrinogen e tšoaroang ka fenofibrate, ho ile ha hlokomeloa ho fokotseha ho hoholo hoa letšoao lena, hammoho le ho bakuli ba nang le lipoprotein tse phahameng. Ha ho phekoloa fenofibrate, ho fokotseha hoa bongata ba liprotheine tsa C-reactive le matšoao a mang a tšoaetso.

Bakeng sa bakuli ba nang le dyslipidemia le hyperuricemia, menyetla e eketsehileng ke hore fenofibrate e na le phello ea uricosuric, e lebisang ho fokotseha ha khatello ea uric acid e ka bang 25%.

Thutong ea bongaka, fenofibrate e bontšitsoe ho fokotsa ho kopana ha liplatelete ho bakoang ke adenosine diphosphate, arachidonic acid, le epinephrine.

Matšoao a ho sebelisoa

Ntle le lijo le litlhare tse ling tse seng tsa lithethefatsi

(boikoetliso ba 'mele, ho fokotsa boima ba' mele) maemong a latelang:

hypertriglyceridemia e nang le cholesterol e tlaase kapa e se nang eona

- hyperlipidemia e tsoakiloeng e le teng moo ho nang le likhohlano kapa ho hloka mamello ho li-statins

- hyperlipidemia e tsoakiloeng ho bakuli ba nang le kotsi e phahameng ea pelo le ho feta le li-statins tse sa sebetseng hantle ho lokiseng triglycerides le cholesterol e phahameng haholo.

Tekanyetso le tsamaiso

Tricor Tricor ea 145 mg e nkuoa ka nako efe kapa efe ea letsatsi, ho sa tsotelehe lijo tse ngata, Letlapa le lokela ho metsoa ka botlalo, ntle le ho hlafuna, ka khalase ea metsi.

Hammoho le lijo, Tricor 145 mg e laetsoe lithutong tse telele, ts'ebetso ea eona e lokelang ho beoa leihlo nako le nako.

Ho sebetsa hantle ho phekoloa ho hlahlojoa ho sebelisoa boleng ba lipid spectrum (cholesterol e felletseng, cholesterol e fokolang, triglycerides).

Haeba nakong ea likhoeli tse 3 ho se na ntlafatso profilse ea lipid, ho nahaneloa ho khethoa ha kalafo e eketsehileng kapa e 'ngoe.

Batho ba baholo ba fuoa Letlapa le le leng la Tricor 145 mg 1 nako ka letsatsi. Bakuli ba nkang pilara e le 'ngoe ea fenofibrate 200 mg e ka fetohela ho nka Letlapa le le leng la Tricor 145 mg ka letsatsi ntle le tokiso ea tekanyetso e eketsehileng.

Bakuli ba noang letlapa le le leng la fenofibrate 160 mg ka letsatsi, ba ka fetohela ho nka Letlapa le le leng la Tricor 145 mg ntle le tokiso ea tekanyetso e eketsehileng.

Bakuli ba baholo ntle le ho hloleha ho phekoloa ke pheko, ho khothaletsoa tekanyetso ea batho ba baholo e tloaelehileng.

Ts'ebeliso ea lithethefatsi ho bakuli ba nang le lefu la sebete ha e ithutoe.

Litlamorao

Liphetho tse latelang tse mpe li ile tsa bonoa nakong ea liteko tsa bongaka tse laoloang ke placebo (n = 2344):

- bohloko ba ka mpeng, ho nyekeloa ke pelo, ho hlatsa, lets'ollo, lefutso (bonolo)

- li-transaminase tse phahameng tsa sebete

- vein thrombosis e tebileng, pulmonary thromboembolism

- Boitšoaro hypersensitivity: letlalo le leputsoa, ​​ho hlohlona, ​​urticaria

- myalgia, myositis, mesifa ea mesifa, bofokoli ba mesifa

- maemo a eketsehang a "creatinine" maling

- ho fokotseha ha boemo ba hemoglobin, ho fokotseha ha se fumanoang ke leukocytes

- alopecia, photosensitivity reaction

- maemo a eketsehang a urea ho plasma ea mali

- o ikutloa o khathetse, o le leseli

Litla-morao tse anngoeng nakong ea ts'ebeliso ea kamora 'maraka (khafetsa ha e tsejoe):

- jaundice, cholelithiasis complication (mohlala, cholecystitis, cholangitis, biliary colic)

karabelo e matla ea letlalo (jk., erythema multiforme, Stevens-Johnson syndrome, chefo e kotsi ea epidermal necrolysis)

Ts'ebeliso ea lithethefatsi Tricor 145 mg

Hammoho le kalafo ea ho ja, sethethefatsi se etselitsoe kalafo ea nako e telele, ts'ebetso ea eona e lokela ho lekoloa nako le nako ka ho khetholla boemo ba lipids bo serum ea mali (cholesterol e felletseng, cholesterol ea LDL, TG).
Haeba kamora ho sebelisa lithethefatsi ka likhoeli tse 'maloa (ho etsa mohlala likhoeli tse 3) boemo ba lipids ka serum ea mali ha bo so fokotsehe ka ho lekana, ho a hlokahala ho nahana ka tumellano ea kalafo kapa mefuta e meng ea kalafo.
Lithapo
Batho ba baholo
Motsoako o khothalelitsoeng ke 145 mg (Letlapa le le 1) hang ka letsatsi. Bakuli ba nkang fenofibrate ka tekanyo ea 200 mg ba ka nkeloa sebaka ke pilisi e le 'ngoe ea Tricor 145 mg ntle le khetho e eketsehileng ea lethal dose.
Bakuli ba baholo
Bakeng sa bakuli ba tsofetseng, ho khothalletsoa tekanyetso e tloaelehileng ea batho ba baholo.
Bakuli ba nang le ho hloleha ha meno
Bakuli ba nang le ho se sebetse hantle ha renal ba hloka ho fokotsa tekanyetso. Bakuli ba joalo ba eletsoa hore ba noe lithethefatsi tse nang le litekanyetso tse tlase tsa fenofibrate (100 mg kapa 67 mg).
Bana
Tricor 145 mg e qhekelloa bakeng sa kalafo ea bana.
Lefu la sebete
Ts'ebeliso ea lithethefatsi ho bakuli ba nang le mafu a sebete ha e so ithutoe.
Mokhoa oa kopo
Matlapa a tlameha ho metsoa ka botlalo ka khalase ea metsi.
Litafole tsa Traicor tsa 145 mg li ka nooa nako efe kapa efe motšehare, ho sa tsotelehe lijo tse ngata.

Tricor ea Contraindication 145 mg

Hepatic insufficiency (ho kenyelletsa le biliary cirrhosis), ho se sebetse hantle ha lesea, hypersensitivity ho fenofibrate kapa likarolo tse ling tsa lithethefatsi, photosensitivity kapa mokhoa oa ho nka lifoto nakong ea kalafo ka fibrate kapa ketoprofen nakong e fetileng, lefu la nyooko ea senya ea nyooko.
Tricor 145 mg ha ea lokela ho nkuoa ho bakuli ba nang le allergy ho peanut butter kapa soya lecithin, kapa lihlahisoa tse amanang (kotsi e ka bang ea karabelo ea hypersensitivity).

Litla-morao tsa lithethefatsi Tricor 145 mg

Litlamorao li bontšoa ke khafetsa ka tsela ena: khafetsa (1/10), khafetsa (1/100, ≤1 / 10), hangata (1/1000, ≤1 / 100), ka seoelo (1/10 000, ≤1 / 1000), haholo ka seoelo (1/100 000, ≤1 / 10 000), ho kenyeletsoa linyeoe tse ikhethileng.
Ho tsoa pampiring ea ka mpeng
Khafetsa: bohloko ba ka mpeng, ho nyekeloa ke pelo, ho hlatsa, lets'ollo le ho hlapoloha, ho lekana ka boholo.
Khafetsa: pancreatitis.
Karolong ea sebete le pampiri ea biliary
Khafetsa: keketseho e leka-lekaneng ea li-serum transaminases (bona LITLHAKISO TSE LING TSA HO BONAHALA).
Nako le nako: sebopeho sa majoe ka gallbladder.
Ka seoelo: linyeoe tsa lefu la sebete. Haeba matšoao (mohlala, jaundice, ho hlohlona) a supa ho hlaha hoa lefu la hepatitis, liteko tsa laboratori li lokela ho etsoa ho netefatsa lefu mme, haeba ho hlokahala, tlohela lithethefatsi (bona LITLHAKISO TSE BONOLO).
Karolong ea letlalo le lisele tse ling
E sa tloaelehang: lepotlapotla, ho hlohlona, ​​likokoanyana, kapa karabelo ea photosensitivity.
Ka seoelo: alopecia.
Haholoholo: photosensitivity ea letlalo le nang le erythema, ponahalo ea li-vesicles kapa li-nodule libakeng tsa letlalo tse ileng tsa pepesetsoa ke mahlaseli a letsatsi kapa mahlaseli a maiketsetso a ultraviolet maemong a mang (le kamora ho sebelisoa likhoeli tse ngata ntle le mathata).
Ho tsoa tsamaisong ea musculoskeletal
Ka seoelo: senya myalgia, myositis, mesifa ea mesifa le bofokoli ba mesifa.
Tse sa tloaelehang haholo: rhabdomyolysis.
Ho tsoa ho tsamaiso ea methapo ea pelo
Nako le nako: venous thromboembolism (pulmonary embolism, e tebileng vein thrombosis).
Karolong ea sistimi ea mali le tsamaiso ea methapo
Khafetsa: ho fokotseha ha hemoglobin le lisele tse tšoeu tsa mali.
Ho tsoa tsamaisong ea methapo
Khafetsa: bofokoli ba thobalano, hlooho e bohloko.
Karolong ea sistimi ea ho hema, sefuba le mediastinum
Tse sa tloaelehang: pneumonia e ka hare ho naha.
Liphetho tsa lipatlisiso
Nako le nako: serum creatinine le urea.

Litaelo tse khethehileng bakeng sa ts'ebeliso ea lithethefatsi Tricor 145 mg

Tsamaiso ea Tricor 145 mg e bontšoa ka ho khetheha boteng ba lintlha tse ka bang teng tsa kotsi tse kang khatello ea mali (khatello ea mali) le ho tsuba.
Tabeng ea hypercholesterolemia ea bobeli, pele a qala kalafo le TRICOR 145 mg, ho hlokahala hore a phekole ka nepo maemo a ileng a e baka kapa a felise lisosa tse ling tse kang mofuta o bolailoeng oa lefu la tsoekere la II mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia (mohlala, myeloma ), hyperbilirubinemia, pharmacotherapy (lithibela-pelehi tsa molomo, li-corticosteroids, lithethefatsi tse thibelang lefu lena, li-inhibitors tsa protheine bakeng sa kalafo ea ts'oaetso ea HIV), joala.
Matla a kalafo a lokela ho laoloa ka ho khetholla boemo ba lipids tse serumeng ea mali (kakaretso cholesterol, LDL, TG). Haeba tšusumetso e lekaneng e sa fihlella likhoeli tse 'maloa (mohlala, likhoeli tse 3), ho hlokahala hore u nahane ka ho khethoa ha kalafo e eketsehileng kapa mefuta e meng ea kalafo.
Ho bakuli ba nang le hyperlipidemia ba nkang litokisetso tsa estrogen kapa lithibela-pelehi tse nang le estrogens, ho hlokahala hore ho hlahlojoe hore na hyperlipidemia ke ntho ea mantlha kapa ea tšimolohong, hobane tšebeliso ea li-estrogens tsa molomo e ka eketsa maemo a lipid.
Ts'ebetso ea sebete
Joalo ka ts'ebeliso ea lithethefatsi tse ling tse fokotsang lipid, keketseho ea ts'ebetso ea transaminase e ile ea hlokomeloa ho bakuli ba bang. Maemong a mangata, e ne e le ea nakoana le e bonolo, hape e le asymptomatic. Ho khothalletsoa ho hlahloba tšebetso ea li-transaminase likhoeli tse ling le tse ling tse 3 nakong ea likhoeli tsa 12 tsa kalafo. Tlhokahalo ea ho hlokomela boemo ba bakuli ba bontšitseng keketseho ea boemo ba liprotheine. Ka keketseho ea boemo ba AlAT le AsAT ka makhetlo a fetang a 3 ha ho bapisoa le moeli o kaholimo oa tloaelo, lithethefatsi li tlameha ho hlakoloa.
Pancreatitis
Ho bakuli ba ileng ba nka fenofibrate, linyeoe tsa pancreatitis li ile tsa bonoa. Ho hlaha ha eona e ka ba sesosa sa ho hloleha ha kalafo ho bakuli ba nang le hypertriglyceridemia e tobileng, phello e tobileng ea lithethefatsi kapa ka lebaka le leng, mohlala, lejoe ho ducts tsa bile kapa ho thijoa ha duct e tloaelehileng.
Mmino
Litlamorao tse kotsi ho mesifa, ho kenyelletsa le linyeoe tse sa tloaelehang tsa rhabdomyolysis, li hlokometsoe ka li-fibrate le lithethefatsi tse ling tse fokotsang lipid. Khafetsa matla a eona a eketseha ka hypoalbuminemia kapa ho hloleha ha renal. Tšusumetso e ka bang chefo ho mesifa ho bakuli ba ferekanyang myalgia, makhopho le bofokoli ba mesifa, hammoho le keketseho e tšoailoeng ea CPK (makhetlo a 5 ha e bapisoa le tloaelo), e lokela ho tsotelloa. Maemong ana, kalafo e nang le TRICOR 145 mg e tlameha ho khaotsa.
Haeba ho na le mabaka a khethollang tloaelo ea myopathy le / kapa rhabdomyolysis, ho kenyelletsa le lilemo tse fetang 70, mafu a mesifa ea lefutso ho mokuli kapa litho tsa lelapa, lefu la liphio, hypothyroidism, kapa tšebeliso e mpe ea joala, bakuli ba ka ba le kotsi e eketsehileng ea rhabdomyolysis. Ho bakuli ba joalo, ho hlokahala ho hlahloba ka hloko melemo le likotsi tsa kalafo ka Tricor 145 mg.
Kotsi ea litlamorao tse chefo mesifa e ka eketseha haeba moriana o laetsoe ka nako e le ngoe fiberrate kapa HMG-CoA reductase inhibitor, haholoholo ha ho e-na le maloetse a mesifa a kopaneng. Ka hona, ho bohlokoa ho fana ka motsoako oa fenofibrate le statin feela ho bakuli ba nang le dyslipidemia e kopaneng le kotsi e kholo ea lefu la pelo ha ho se na nalane ea maloetse a mesifa le ho etsa kalafo e shebelloe haufi le ho bona hore na ho ka ba le chefo e kae mesifa.
Ts'ebetso ea liphio
Phekolo e lokela ho khaotsa haeba boemo ba "creatinine" bo eketsehile ka karolo e fetang 50% ha e bapisoa le moeli o kaholimo o tloaelehileng. Ho khothalletsoa ho nahana ka tlhoko ea ho lekola litekanyetso tsa "creatinine" likhoeling tsa pele kamora ho qala kalafo.
Tricor 145 mg e na le lactose, kahoo bakuli ba nang le mafu a lefutso joalo ka galactose ts'oarello, khaello ea Lappase ea lactase kapa glubrose-galactose malabsorption ha ea lokela ho nka lithethefatsi.
Tricor 145 mg e na le sucrose, ka hona bakuli ba nang le mafu a lefutso joalo ka ho hloka ts'oarelo ha fructose, glucose-galactose malabsorption kapa sucrose-isomaltase ha baa lokela ho nka sethethefatsi sena.
Sebelisa nakong ea bokhachane le pelehi
Lintlha tse lekaneng mabapi le tšebeliso ea fenofibrate nakong ea kemolo ha li fumanehe. Lithuto tsa liphoofolo ha lia hlahisa litlamorao tsa teratogenic. Litlamorao tsa emong e bontšitsoe ka litekanyetso tsa chefo ho mme. Kotsi e ka bang teng ho batho ha e tsejoe, ka hona, Tricor 145 mg e ka sebelisoa nakong ea bokhachane feela kamora tlhahlobo e hlokolosi ea tekanyo ea melemo / kotsi.
Ha ho na data ea ho fanoa ha fenofibrate le / kapa metabolites ea eona ka lebese la matsoele, ka hona, Tricor 145 mg ha ea lokela ho nkuoa ke bo-mme ba anyang matsoele.
Bokhoni ba ho susumetsa sekhahla sa karabelo ha u khanna makoloi kapa u sebetsa ka mekhoa e meng. Ha ho litlamorao tse ileng tsa bonoa.

Litšebelisano tsa Lithethefatsi Tricor 145 mg

Li-anticoagulants tsa molomo
Fenofibrate e ntlafatsa phello ea li-anticoagulants tsa molomo mme e ka eketsa monyetla oa ho tsoa mali. Ho khothalletsoa hore tekanyetso ea li-anticoagulants e fokotsehe ke 1/3 qalong ea kalafo ebe keketseho ea eona butle-butle, haeba ho hlokahala, tlasa taolo ea INR (karolelano e tloaelehileng ea machabeng).
Cyclosporin
Maemo a 'maloa a matla a a sa sebetseng hantle a renal a ile a bonoa ka tšebeliso e le' ngoe ea fenofibrate le cyclosporine, ka hona, ho bakuli ba joalo, ts'ebetso ea liphio e lokela ho hlahlojoa ka hloko. Phekolo e nang le TRICOR 145 mg e lokela ho emisoa haeba ho na le litšitiso tse matla tsa paramente ea laboratori.
HMG-CoA reductase inhibitors le li-fibrate tse ling
Kotsi ea tšenyo e tebileng ea mesifa e chefo e eketsoa ha e sebelisoa le HMG-CoA reductase inhibitors kapa li-fibrate tse ling. Motsoako ona o lokela ho sebelisoa ka hloko 'me o shebe ka hloko ponahalo ea matšoao a nang le chefo ho mesifa (bona LITLHAKISO TSE BONAHALANG).
Li-Enzymes tsa cytochrome P450
Patlisiso in vitro u sebelisa li-microsomes tsa batho ba hepatic, fenofibrate le fenofibric acid ha se li-inhibitors tsa cytochrome (CYP) P450 isoforms CYP 3A4, CYP 2D6, CYP 2E1 kapa CYP 1E2. Ke li-inhibitors tse fokolang tsa CYP 2C19 le CYP 2A6 mme li na le phello e fokolang kapa e leka-lekaneng ea ho thibela CYP 2C9 maemong a phekolo, a lokelang ho tsotelloa ha ho fanoa ka lithethefatsi tse nang le metabolized ka ho nka karolo ha li-istoorms tsa cytochrome P450.